

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **Clarification Announcement in relation to Chinese Version of the Announcement**

Reference is made to the announcement of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 15 July 2022 (the “**Announcement**”).

The board of directors (the “**Board**”) of the Company wishes to clarify that the following Chinese translation corresponding to the last section on page 2 of the English version of the Announcement, was inadvertently omitted on the Chinese version of the Announcement (the “**Chinese Announcement**”) and shall be the last section on page 2 of the Chinese Announcement:

“**刊發業績公告及年報**

本更新公告已刊登於聯交所網站([www.hkexnews.hk](http://www.hkexnews.hk))及本公司網站([www.extrawell.com.hk](http://www.extrawell.com.hk))。年報將於二零二二年七月底前寄發予本公司股東及於上述網站刊載。”

Save for the aforesaid, all the information and contents of the Chinese Announcement remain unchanged. The above clarification does not affect all the information and contents of the English version of the Announcement.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 18 July 2022

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*